SAGHE

Safety and Appropriateness of Growth hormone treatments in Europe

Coordinatore	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS    more  Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Mr. Nome: Christophe Cognome: Misse Email: send email Telefono: 33144841770 Fax: 33144841788
Nazionalità Coordinatore	France [FR]
Totale costo	3˙878˙026 €
EC contributo	2˙989˙154 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-B
Funding Scheme	CP-FP
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-06-01   -   2012-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS  Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Mr. Nome: Christophe Cognome: Misse Email: send email Telefono: 33144841770 Fax: 33144841788	FR (PARIS)	coordinator	627˙312.00
2	UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA  Organization address address: VIA ORAZIO RAIMONDO 18 city: ROMA postcode: 173 contact info Titolo: Prof. Nome: Massimo Cognome: Andreoni Email: send email Telefono: 390673000000 Fax: 39067236605	IT (ROMA)	participant	443˙442.00
3	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Mr. Nome: Thomas Cognome: Walstam Email: send email Telefono: +46 8 517 73487 Fax: +46 8 51771774	SE (STOCKHOLM)	participant	418˙291.00
4	UNIVERSITAET LEIPZIG  Organization address address: RITTERSTRASSE 26 city: LEIPZIG postcode: 4109 contact info Titolo: Prof. Nome: Wieland Cognome: Kiess Email: send email Telefono: +49 341 9726330 Fax: +49 341 9726349	DE (LEIPZIG)	participant	320˙366.00
5	CLINIQUES UNIVERSITAIRES SAINT-LUC  Organization address address: AVENUE HIPPOCRATE 10 city: BRUXELLES postcode: 1200 contact info Titolo: Mr. Nome: Michel Cognome: Van Hassel Email: send email Telefono: 3227641510 Fax: 3227641501	BE (BRUXELLES)	participant	249˙563.00
6	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Greta Cognome: Borg-Carbott Email: send email Telefono: +44 207679 6135 Fax: +44 2 07 8132 849	UK (LONDON)	participant	233˙339.00
7	UNIVERSITAET BERN  Organization address address: Hochschulstrasse 4 city: BERN postcode: 3012 contact info Titolo: Prof. Nome: "Primus-Eugen, Josef" Cognome: Mullis Email: send email Telefono: +41 31 632 9552 Fax: +41 31 632 9550	CH (BERN)	participant	205˙180.00
8	STICHTING KIND EN GROI  Organization address address: WESTZEEDIJK 106 city: ROTTERDAM postcode: 3016 AH contact info Titolo: Prof. Nome: Anita Cognome: Hokken-Koelega Email: send email Telefono: 31102251533 Fax: 31102250133	NL (ROTTERDAM)	participant	205˙118.00
9	INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL  Organization address address: Old Brompton Road 123 city: LONDON postcode: SW7 3RP contact info Titolo: Ms. Nome: Lydia Cognome: Turner Email: send email Telefono: +44 207 153 5219 Fax: +44 207 153 5534	UK (LONDON)	participant	151˙751.00
10	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: +44 161 275 7114 Fax: +44 161 275 2445	UK (MANCHESTER)	participant	134˙792.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Recombinant growth hormone (GH) has been used since 1985. Current indications for GH use in children include GH deficiency and an increasing number of conditions where childhood short stature is not primarily due to deficient GH secretion. Approximately 40 000 children in the EU are treated with daily injections of GH. The efficacy of GH to increase adult height is undisputed in children with severe GH deficiency but is more limited in other indications where current estimates suggest a gain of about 1 cm of adult height per year of treatment. The clinical significance of height gains has been poorly evaluated. The possibility has been raised that GH use in childhood might increase the risk of cancer later in life. However, little data is available to further explore this concern. SAGhE is an integrated consortium of paediatric endocrinologist, epidemiologists and biostatisticians that will collect and analyse data to address the questions of appropriateness and safety of childhood GH treatments. The impact on both height and psychosocial components will be evaluated on a large unbiased metacohort of patients followed to adult height. Safety will be evaluated by analysing long term mortality and long term cancer incidence. The data obtained will then be integrated and disseminated to several levels of users. SAGhE will contribute to the aims of the FP7 Health work programme and to the new Community Action programme of public Health in the field of better use of medicines. It will realize the application of evidence-based medicine in Europe, by the size and design of the study, the independence and scientific quality of data analysis and its translation into evidence-based guidelines. It will be comprehensive at the EU level and will test for national differences. It will address patient safety, one of the key points of the work programme. SAGhE is unique worldwide in its design, size and potential to answer important questions raised on childhood GH treatments.'

Introduzione (Teaser)

Recombinant growth hormone (GH) treatments have been the norm for treating childhood short stature resulting from factors such as GH deficiency. Globally, concerns have been raised about the association between childhood GH treatments and long-term mortality due to cancer incidence in adulthood.